Stockreport

Jazz Pharmaceuticals Scores FDA Priority Review for Ziihera Combinations in First-Line HER2+ Gastroesophageal Cancer [TheStreet.com]

Jazz Pharmaceuticals plc - Ordinary Shares  (JAZZ) 
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: jazzpharma.com
PDF FDA accepted and granted Priority Review to its supplemental Biologics License Application (sBLA) for Ziihera® (zanidatamab-hrii) combinations in first-line HER2-positiv [Read more]